BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Dear Doctor Letter (Rote-Hand-Brief) on OCALIVA® (obeticholic acid): differential dosing recommendations in primary biliary cholangitis (PBC) patients with moderate and severe hepatic impairment

Active substance: obeticholic acid

Due to the risk of serious liver injury in patients with moderate and severe hepatic impairment, all patients are to be monitored by way of laboratory and clinical assessment for progression of the PBC disease during treatment with obeticholic acid in order to determine whether dosage adjustment is needed.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 361KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK